Physician profile

Scott William Taylor

Podiatrist · North Syracuse, NY

NPI 1164647715

$518.39

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$153.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Depuy Synthes Sales INC. $112.45 2022
Novo Nordisk INC $87.74 2022
Medtronic, INC. $80.81 2022
Abbott Laboratories $71.68 2023 Proclaim
Averitas Pharma INC. $60.17 2024 Qutenza
Medline Industries LP $43.31 2022
Paragon 28, INC. $25.42 2019
Abbvie INC. $21.75 2023 Vraylar
Wright Medical Technology, INC. $15.06 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott William Taylor

$518.39

in general payments reported 2019-2025

Years
2019-2024
Top company
Depuy Synthes Sales INC.

https://glasscript.com/doctor/482175/scott-william-taylor

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.